Skip to main content
Clinical Trials/NCT06239766
NCT06239766
Completed
Not Applicable

Assessing Breast Cancer Risk Prior to Gender-Affirming Chest Masculinization Surgery in Transgender and Gender-Diverse Persons

Medical College of Wisconsin1 site in 1 country25 target enrollmentMarch 15, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Medical College of Wisconsin
Enrollment
25
Locations
1
Primary Endpoint
Rate of uptake of oncologic risk reducing mastectomies as part of chest masculinization surgery in TGD persons at risk of breast cancer based on validated models.
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The population of transgender and gender-diverse (TGD) persons in Wisconsin and the U.S. is steadily increasing. As this population grows, the number of individuals seeking gender-affirming therapies, including gender-affirming operations and gender-affirming hormone therapy, is also growing. An example of gender-affirming surgery is chest masculinization surgery, in which most breast tissue is removed in a person assigned female or intersex at birth to allow the chest to appear masculine. Gender-affirming chest masculinization surgery is not generally considered equivalent to an oncologic mastectomy, which aims to removal all breast tissue for future breast cancer reduction or current breast cancer treatment.

The goals of this investigation are to 1) determine the percent of TGD persons considering chest masculinization surgery who have an elevated lifetime risk of breast cancer development and/or a pathogenic genetic mutation; 2) measure the percent who are at risk and choose to undergo risk-reducing mastectomies as part of chest masculinization surgery; and 3) assess and compare self-perceived breast cancer risk with calculated risk.

The results of this study will substantially inform TGD patients and surgeons on the utility of personalized breast cancer risk assessment prior to chest masculinization surgery and the accuracy of self-perceived breast cancer risk in TGD persons.

Registry
clinicaltrials.gov
Start Date
March 15, 2023
End Date
February 1, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Chandler S Cortina

Assistant Professor of Surgery

Medical College of Wisconsin

Eligibility Criteria

Inclusion Criteria

  • ≥18 years old.
  • Assigned female or intersex at birth and identify as non-cisgender.
  • Any individual considering undergoing gender-affirming chest masculinization surgery
  • Ability to communicate in English.
  • Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria

  • \<18 years old.
  • Assigned male sex at birth.
  • Previously underwent chest masculinization surgery or any form of oncological mastectomy for the purposes of risk-reduction or cancer treatment.
  • Any previous or current history of breast cancer, including ductal carcina in situ (DCIS).
  • Inability to communicate in English.

Outcomes

Primary Outcomes

Rate of uptake of oncologic risk reducing mastectomies as part of chest masculinization surgery in TGD persons at risk of breast cancer based on validated models.

Time Frame: 1 year

To determine whether those TGD persons at elevated risk of breast cancer development choose to undergo risk-reducing mastectomies as part of their chest masculinization surgery.

Estimated prevalence of TGD persons seeking chest masculinization surgery who at an elevated breast cancer risk.

Time Frame: 1 year

Validated breast cancer risk calculators (IBIS and Gail) will be used to determine lifetime breast cancer risk of participants enrolled into the study. Ranges and 95% CI will be made to estimate the percent of TGD persons at risk.

Self-perceived breast cancer risk vs calculated breast cancer risk

Time Frame: 1 year

A visual analog scale from 0-100% will be used to compare and assess the self-perceived estimated breast cancer risk with calculated breast cancer risk. 13% is marked as the average cisgender women's risk of breast cancer and participants report their self-perceived risk as single whole integer (ex. 8%, 15%, 25%, etc.) on the scale from 0-100% where 0-12% represents below average risk person and 13-100% represent above average risk.

Study Sites (1)

Loading locations...

Similar Trials